INIFY LABORATORIES AB Stockholm -April 11, 2024 -Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Annual General Meeting onMay 14, 2024 . Please find attached the invitation including agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com. For inquiries, please contact CFOAnn-Charlotte Linderoth at e-mail: ann -charlotte.linderoth@inify.com or: ir@inify.com. ### AboutInify Laboratories Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate.The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based inSweden , became independent in 2022 through a spin-off fromContextVision (https://www.contextvision.com/), with 40 years of experience within digital imaging for medical applications. It is listed onEuronext GrowthOslo under the ticker INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK). This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
